Cho H, Lim J
    
    
    Mol Cells. 2024; 47(11):100126.
  
  
    PMID: 39426686
    
          PMC: 11577206.
    
          DOI: 10.1016/j.mocell.2024.100126.
      
 
                                  
  
    Habib S
    
    
    World J Gastrointest Pathophysiol. 2024; 15(4):93606.
  
  
    PMID: 39220834
    
          PMC: 11362842.
    
          DOI: 10.4291/wjgp.v15.i4.93606.
      
 
                                  
  
    Kleiman D, Arad Y, Azulai S, Baker A, Bergel M, Elad A
    
    
    Mol Metab. 2024; 86:101979.
  
  
    PMID: 38945296
    
          PMC: 11278880.
    
          DOI: 10.1016/j.molmet.2024.101979.
      
 
                                  
  
    Stefanakis K, Kokkinos A, Argyrakopoulou G, Konstantinidou S, Simati S, Kouvari M
    
    
    Diabetes Obes Metab. 2023; 25(9):2561-2574.
  
  
    PMID: 37246799
    
          PMC: 10524619.
    
          DOI: 10.1111/dom.15141.
      
 
                                  
  
    Zaina A, Prencipe N, Golden E, Berton A, Arad E, Abid A
    
    
    Endocrine. 2023; 80(3):491-499.
  
  
    PMID: 37000406
    
    
          DOI: 10.1007/s12020-023-03352-4.
      
 
                              
              
                              
                                      
  A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity.
  
    Chen L, Zhang J, Sun Y, Zhao Y, Liu X, Fang Z
    
    
    Nat Commun. 2023; 14(1):1405.
  
  
    PMID: 36918550
    
          PMC: 10014962.
    
          DOI: 10.1038/s41467-023-36946-7.
      
 
                                          
                                                          
  Pharmacoeconomic analysis (CER) of Dulaglutide and Liraglutide in the treatment of patients with type 2 diabetes.
  
    Su Y, Zhang S, Wu Z, Liu W, Chen J, Deng F
    
    
    Front Endocrinol (Lausanne). 2023; 14:1054946.
  
  
    PMID: 36755915
    
          PMC: 9899911.
    
          DOI: 10.3389/fendo.2023.1054946.
      
 
                                          
                                                          
  The Enteroendocrine System in Obesity.
  
    Miedzybrodzka E, Reimann F, Gribble F
    
    
    Handb Exp Pharmacol. 2022; 274:109-129.
  
  
    PMID: 35419621
    
    
          DOI: 10.1007/164_2022_582.
      
 
                                          
                                                          
  Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes.
  
    Tan Q, Akindehin S, Orsso C, Waldner R, DiMarchi R, Muller T
    
    
    Front Endocrinol (Lausanne). 2022; 13:838410.
  
  
    PMID: 35299971
    
          PMC: 8921987.
    
          DOI: 10.3389/fendo.2022.838410.
      
 
                                          
                                                          
  Medium-chain triglycerides inhibit long-chain triglyceride-induced GIP secretion through GPR120-dependent inhibition of CCK.
  
    Murata Y, Harada N, Kishino S, Iwasaki K, Ikeguchi-Ogura E, Yamane S
    
    
    iScience. 2021; 24(9):102963.
  
  
    PMID: 34466786
    
          PMC: 8382997.
    
          DOI: 10.1016/j.isci.2021.102963.
      
 
                                          
                                                          
  Fasting Plasma GLP-1 Is Associated With Overweight/Obesity and Cardiometabolic Risk Factors in Children and Adolescents.
  
    Stinson S, Jonsson A, Lund M, Frithioff-Bojsoe C, Holm L, Pedersen O
    
    
    J Clin Endocrinol Metab. 2021; 106(6):1718-1727.
  
  
    PMID: 33596309
    
          PMC: 8118577.
    
          DOI: 10.1210/clinem/dgab098.
      
 
                                          
                                                          
  Targeting lipid GPCRs to treat type 2 diabetes mellitus - progress and challenges.
  
    Ghislain J, Poitout V
    
    
    Nat Rev Endocrinol. 2021; 17(3):162-175.
  
  
    PMID: 33495605
    
    
          DOI: 10.1038/s41574-020-00459-w.
      
 
                                          
                                                          
  Antagonizing somatostatin receptor subtype 2 and 5 reduces blood glucose in a gut- and GLP-1R-dependent manner.
  
    Jepsen S, Wewer Albrechtsen N, Windelov J, Galsgaard K, Hunt J, Farb T
    
    
    JCI Insight. 2021; 6(4).
  
  
    PMID: 33434183
    
          PMC: 7934931.
    
          DOI: 10.1172/jci.insight.143228.
      
 
                                          
                                                          
  The distribution and chemical coding of enteroendocrine cells in Trypanosoma cruzi-infected individuals with chagasic megacolon.
  
    Rocha Martins P, Fakhry J, de Oliveira A, Moreira T, Fothergill L, Oliveira E
    
    
    Histochem Cell Biol. 2021; 155(4):451-462.
  
  
    PMID: 33404704
    
    
          DOI: 10.1007/s00418-020-01947-w.
      
 
                                          
                                                          
  Effect of the glucagon-like peptide-1 analogue liraglutide versus placebo treatment on circulating proglucagon-derived peptides that mediate improvements in body weight, insulin secretion and action: A randomized controlled trial.
  
    Kim S, Abbasi F, Nachmanoff C, Stefanakis K, Kumar A, Kalra B
    
    
    Diabetes Obes Metab. 2020; 23(2):489-498.
  
  
    PMID: 33140542
    
          PMC: 7856054.
    
          DOI: 10.1111/dom.14242.
      
 
                                          
                                                          
  HOMA-IR in acromegaly: a systematic review and meta-analysis.
  
    Biagetti B, Aulinas A, Casteras A, Perez-Hoyos S, Simo R
    
    
    Pituitary. 2020; 24(2):146-158.
  
  
    PMID: 33085039
    
    
          DOI: 10.1007/s11102-020-01092-6.
      
 
                                          
                                                          
  Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies.
  
    Ma L, Luo D, Yang T, Wu S, Li M, Chen C
    
    
    BMC Endocr Disord. 2020; 20(1):126.
  
  
    PMID: 32811475
    
          PMC: 7433060.
    
          DOI: 10.1186/s12902-020-0545-2.
      
 
                                          
                                                          
  Leveraging the Gut to Treat Metabolic Disease.
  
    Gimeno R, Briere D, Seeley R
    
    
    Cell Metab. 2020; 31(4):679-698.
  
  
    PMID: 32187525
    
          PMC: 7184629.
    
          DOI: 10.1016/j.cmet.2020.02.014.
      
 
                                          
                                                          
  Glucagon-like peptide 1 (GLP-1).
  
    Muller T, Finan B, Bloom S, DAlessio D, Drucker D, Flatt P
    
    
    Mol Metab. 2019; 30:72-130.
  
  
    PMID: 31767182
    
          PMC: 6812410.
    
          DOI: 10.1016/j.molmet.2019.09.010.
      
 
                                          
                                                          
  Establishment of a model for equine small intestinal disease: effects of extracorporeal blood perfusion of equine ileum on metabolic variables and histological morphology - an experimental ex vivo study.
  
    Unterkofler M, McGorum B, Milne E, Licka T
    
    
    BMC Vet Res. 2019; 15(1):400.
  
  
    PMID: 31703590
    
          PMC: 6839147.
    
          DOI: 10.1186/s12917-019-2145-9.